Stephen Norris
About Stephen Norris
Stephen Norris is a Senior Scientist at Bristol Myers Squibb in San Diego, California, with over 16 years of experience in Small Molecule Drug Discovery.
Current Role at Bristol Myers Squibb
Stephen Norris is currently a Senior Scientist at Bristol Myers Squibb in San Diego, California. He has been in this role since 2021, where he continues to contribute his expertise in Small Molecule Drug Discovery. His responsibilities include leading research projects, optimizing compounds, and advancing the development of new drug candidates.
Professional Experience at Bristol Myers Squibb
Stephen Norris has held multiple roles at Bristol Myers Squibb in San Diego, California. Before becoming a Senior Scientist in 2021, he worked as a Scientist for 10 months from 2020 to 2021 and as a Senior Associate Scientist for one year from 2019 to 2020. During his tenure, he has engaged in various projects focused on drug discovery and development.
Previous Roles at Celgene
Stephen Norris's extensive career at Celgene in San Diego includes a series of ascending roles over 12 years. Starting as a Research Associate I from 2005 to 2007, he progressed to Research Associate II from 2007 to 2009. He was then promoted to Senior Research Associate from 2009 to 2011, followed by Associate Scientist from 2011 to 2016. His final role at Celgene was Senior Associate Scientist, which he held from 2016 to 2019. These roles involved working on various small molecule drug discovery projects.
Education and Specialization
Stephen Norris holds a Bachelor of Science degree in Chemistry from the University of California, Los Angeles (UCLA), which he completed between 2002 and 2005. His academic background laid the foundation for his expertise in Structure-Activity Relationship (SAR) development and compound optimization, areas he has applied in over 16 years of industry experience.
Co-Inventor and Development Work
Stephen Norris has co-invented three development candidates: CC-90001, CC-90005, and CC-94676. His contributions to these projects demonstrate his deep involvement and expertise in the field of small molecule drug discovery. These advancements illustrate his capability to contribute significantly to the teams he works with, delivering viable development candidates.